Reduced mRNA and protein expression of BCL-2 versus decreased mRNA and increased protein expression of BAX in breast cancer brain metastases: a real-time PCR and immunohistochemical evaluation.
Brain metastases are an increasingly common complication in breast cancer patients. Apoptosis regulating genes are promising candidates for further treatment options. We examined the mRNA and protein expression of p53, BCL-2 and BAX in breast cancer brain metastases versus primary tumors. In a two-step approach p53, BCL-2 and BAX mRNA expression in ductal invasive breast cancer brain metastases was examined by: (1) reverse transcription-polymerase chain reaction (RT-PCR) mRNA expression screening (band appearance in relation to an internal standard) and (2) quantitative real-time RT-PCR (CT-values in relation to an internal standard). Protein expression using immunohistochemistry. Results were compared with primary tumors. We found significantly lower BCL-2 mRNA and protein expression in breast cancer brain metastases versus primary tumors. P53 mRNA and protein expression was also lower in metastases. However, this difference was only significant on mRNA but not on the protein level. BAX expression evaluation revealed was contradictory results: mRNA expression was significantly lower whereas protein expression was significantly higher in metastatic lesions. The mRNA and protein expression of p53 and BCL-2 seems to be reduced in breast cancer brain metastases. BAX mRNA and protein may be regulated differentially in metastatic lesions.